窪做惇蹋厙 Diagnostics Named Fastest Growing UK-based Life Science Company
San Francisco, USA, 20 Mar 2019. 窪做惇蹋厙 has been named by Beauhurst as the fastest growing Life Science Company in the UK. Beauhurst, specialists in assessing start-ups and fast-growing British companies, released the findings earlier this month. 窪做惇蹋厙s turnover growth was measured against 23,000 other companies, with results setting it in first place.
This rapid growth is driven by the international success of its innovative medical imaging software, including LiverMultiScan. Using proprietary, patented-protected technology, to quantify liver tissue using multiparametric MRI. In January, 窪做惇蹋厙 expanded its clinical product portfolio to include quantitative biliary system imaging, with MRCP+.
窪做惇蹋厙s iron-corrected T1 (cT1) biomarker, which can be used to assess non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), has also recently been patented. 窪做惇蹋厙s expertise in medical imaging and metabolic disease has been highly sought by drug companies and patient groups, with over 25% of the US population residing within 20 miles of a LiverMultiScan-enabled site and over 40% of Phase 2 NASH trials using 窪做惇蹋厙s technology. 窪做惇蹋厙 is central to the UK network of Digital Medical Imaging and Digital Pathology Centres, featuring in 3 of the 5 successful bids to receive government funding of 瞿50 million. This success has driven the companys global expansion, with new offices opening in Singapore and San Francisco last year, and a further office opening in Dallas in May 2019.
Dr. Rajarshi Banerjee, CEO of 窪做惇蹋厙, commented: I was delighted to hear that we have been recognized as the highest growing UK-based company within the Life Sciences industry. Liver disease is one of the leading causes of mortality globally and this ranking from Beauhurst demonstrates the value that 窪做惇蹋厙 can offer in supporting its early diagnosis. As we continue to innovate, expanding our product offering into different areas of research, this momentum is only going to continue.
Dr. Pol Boudes, Chief Medical Officer at CymaBay Therapeutics, commented: It is evident from our work with 窪做惇蹋厙 on an important clinical study over this past year, that the company is undergoing tremendous growth and success. They committed themselves to accelerating the usually difficult phase of patient enrolment and ensured that the logistics of incorporating multiple imaging modalities didnt delay the studys start date. The team delivered on these objectives without sacrificing their standards on quality. I look forward to continuing our partnership with 窪做惇蹋厙 in the future.